EndoFold develops a gene delivery platform featuring human protein-based RNA carriers, a computational testing platform, and targeted delivery methods to enable non-viral therapies for cancer, immune, and musculoskeletal diseases. The platform supports delivery of large genetic payloads, such as a full-length human dystrophin RNA template of approximately 23 kb produced in collaboration with Ansa Biotechnologies, achieving robust expression in human cells. Its technology includes Cosmohedra, a physics-based method for predicting structures of symmetric protein complexes up to 40,000 amino acids with near-experimental accuracy in under five minutes on consumer hardware. Most authors of the underlying research are employees, consultants, or shareholders of EndoFold, Inc., including cofounder and CEO Joseph B. Alzagatiti. The company raised early-stage VC funding on March 1, 2025 from BoxOne Ventures and participated in the Magnify accelerator program. EndoFold is headquartered at 2030 47th Avenue in San Francisco, CA, with personnel affiliated in Los Angeles, CA.